OxyRevo

Overview

OxyRevo is the widest-pressure-range single-brand hyperbaric manufacturer in the home and semi-clinical market — founded in 2012 and headquartered in Hangzhou, Zhejiang Province, China. Its catalog spans from entry-level soft-shell portables at 1.5 ATA through 4mm stainless steel hard-shell chambers at 2.0 ATA, with 60+ registered design patents, CE certification, ISO 9001 and ISO 13485 quality-management credentials, TUV certification, and deployment to 3,000+ clients across 87 countries.

The structural value claim is single-brand vertical integration across two pressure tiers, at price points ($2,500–5,500) that are meaningfully below both US-domestic alternatives and European hard-shell specialists. For international buyers or US buyers comfortable with non-FDA-cleared China-direct sourcing, OxyRevo delivers an unusually complete product family from one manufacturer rather than requiring multi-brand sourcing.

The central editorial caveat must be stated at the top: OxyRevo chambers are not FDA-cleared for the US market. The FDA-cleared HBOT indications — decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, radiation tissue injury, and a set of other specific clinical conditions — require medical supervision in clinical chamber settings at 2.0–3.0 ATA and do not map to wellness or biohacking use of home chambers. OxyRevo’s chambers, like all home-use hyperbaric devices from any brand, are described by their manufacturers for general wellness purposes. Any off-label use beyond that framing is the buyer’s responsibility to evaluate with a qualified physician.

Note: This review is based on OxyRevo’s published specifications, patent filings, certification documentation, and publicly available client data. No OxyRevo chamber was physically tested by this editorial team.

Pressure tier and chamber type comparison

OxyRevo’s catalog is structured around two pressure tiers — the critical distinction for any hyperbaric purchase decision:

Chamber type	Pressure	Shell material	Occupancy	Notable model
Soft-shell portable	1.5 ATA	Medical-grade TPU	Single	Standard portable line
Hard-shell residential	2.0 ATA	4mm stainless steel	Single	Space60 recliner
Hard-shell accessible	2.0 ATA	4mm stainless steel	Wheelchair-accessible	Heal40

For comparison across the broader market:

• FDA-cleared US soft-shell (Newtowne, Summit to Sea): 1.3 ATA only
• OxyRevo soft-shell: 1.5 ATA — meaningfully above the 1.3 ATA FDA-cleared ceiling, not FDA-cleared
• OxyRevo hard-shell: 2.0 ATA — matches Henshaw MonoZen and AHC 30D/34D pressure tier
• European hard-shell (OxyHelp, Henshaw): 1.5–2.0 ATA, with CE certification
• Clinical monoplace chambers: 2.0–2.4 ATA, FDA-cleared, hospital installation

The 1.5 ATA soft-shell deserves explicit framing: no US-market FDA-cleared consumer soft-shell chamber operates above 1.3 ATA. OxyRevo’s soft-shell at 1.5 ATA is above that ceiling. This is either a meaningful advantage (higher pressure for protocols requiring it) or a moot distinction depending on the buyer’s protocol and risk tolerance around non-FDA-cleared devices.

The soft-shell line — medical-grade TPU, heat-welded construction

OxyRevo’s soft-shell chambers use medical-grade TPU (thermoplastic polyurethane) rather than the lower-grade nylon-fabric construction common in budget Chinese-direct alternatives. The construction method is specified as heat-welded rather than glued — a manufacturing distinction that matters for long-term structural integrity under repeated pressurization cycles.

Key specifications (as published):

• Material: medical-grade TPU
• Construction: heat-welded seams (not adhesive bonded)
• Pressure: 1.5 ATA
• Configuration: single-occupant portable

For buyers choosing between Chinese-direct soft-shell alternatives, the TPU material specification and heat-welded construction are meaningful differentiation points versus unspecified-fabric glued-seam budget chambers. For buyers comparing OxyRevo soft-shell to FDA-cleared US alternatives (Newtowne, Summit to Sea, OxyHealth), the regulatory gap remains: OxyRevo’s soft-shell chambers do not carry FDA 510(k) clearance.

The hard-shell line — 4mm stainless steel, 2.0 ATA

This is OxyRevo’s highest-differentiation offering. The hard-shell chambers use 4mm stainless steel construction — the same material-grade and wall thickness used in European clinical-adjacent hard-shell products (OxyHelp, Henshaw) rather than the softer metals or composites used in some Asian-market hard-shell designs.

Space60 — recliner hard-shell

The Space60 is OxyRevo’s premium hard-shell model, distinguished by a recliner seat configuration rather than the standard lying-flat format of most monoplace chambers. The recliner format has meaningful practical implications:

• Claustrophobia mitigation: seated-upright is less claustrophobic than supine for many users
• Usability during sessions: reading, tablet use, or rest in a more natural posture
• Entry/exit ease: walking into an upright chamber is mechanically simpler than lying into a cylinder

Recliner hard-shell configuration is rare at the residential price tier. The Space60 competes directly with the OxyHelp recliner-format chambers on form factor, at a substantially lower price point.

Heal40 — wheelchair-accessible hard-shell

The Heal40 is OxyRevo’s wheelchair-accessible hard-shell model — the only wheelchair-accessible option in this review category. For buyers with mobility impairments, progressive neurological conditions, post-stroke recovery contexts, or clinical facilities needing accessible installation, the Heal40 fills a structural gap that no FDA-cleared US consumer brand addresses.

The editorial framing for the Heal40 specifically: HBOT is not FDA-cleared as a treatment for stroke recovery, multiple sclerosis, cerebral palsy, or other neurological conditions. These are areas of active research with mixed results in published literature. The Heal40’s wheelchair accessibility is a form-factor specification, not an endorsement of HBOT for any neurological indication.

The 60+ design patents and certification stack

OxyRevo’s 60+ design patents are the engineering-credibility differentiator in the Chinese-manufacturer tier, where most competitors publish limited or no patent documentation. Design patents in China’s patent system (外观设计专利) primarily cover aesthetic and structural design elements rather than the deeper invention patents (发明专利) covering underlying technology. The distinction matters for buyers evaluating the patents as an engineering-depth signal — they indicate product development investment and design uniqueness, but are a different category than utility patents on core pressure-delivery technology.

The certification stack is the more operationally relevant credibility layer:

• CE certification: European conformity marking for medical device requirements under EU MDR
• Israeli Standard certification: market-specific regulatory compliance for a demanding technical-regulatory market
• ISO 9001:2015: quality management system standard (manufacturing process)
• ISO 13485:2016: quality management specifically for medical devices — a higher bar than general ISO 9001
• TUV certification: German technical inspection body certification, widely used as quality signal in European and global markets

ISO 13485 is the most substantive certification in this stack for buyers evaluating manufacturing quality. It requires documented quality management specifically in the medical device manufacturing context — covering design controls, risk management, complaint handling, and corrective action processes. It does not substitute for FDA 510(k) clearance in the US market, but it indicates OxyRevo’s manufacturing process meets an international medical-device QMS standard.

The 3,000+ client / 87-country deployment scale

OxyRevo’s claimed 3,000+ clients across 87+ countries is the deployment-scale credibility signal. In a category where many manufacturers are small-volume operations, 3,000+ deployed units across 87 markets indicates meaningful installation volume, logistics infrastructure, and global client experience.

This deployment includes medspas, biohacking centers, athletes, clinical facilities, and home users across international markets. The scale doesn’t substitute for FDA clearance but does suggest the chambers perform at a level supporting ongoing customer relationships across diverse use contexts.

Cost of ownership

Use case	Estimated cost
OxyRevo soft-shell portable (1.5 ATA)	~$2,500–3,500
OxyRevo hard-shell (2.0 ATA, standard)	~$4,000–5,500
Space60 recliner hard-shell (2.0 ATA)	At or above $5,500 end of range
Heal40 wheelchair-accessible (2.0 ATA)	Custom pricing — contact OxyRevo

For comparison:

• Newtowne K051759 (FDA-cleared soft-shell, 1.3 ATA): ~$4,495
• Summit to Sea K072757 (FDA-cleared soft-shell, 1.3 ATA): ~$3,800–6,500
• Macy-Pan (China-direct soft-shell, various ATA): ~$2,500–5,000
• OxyHelp (European hard-shell, 1.5–2.0 ATA): ~$10,000–20,000
• Henshaw MonoZen (UK hard-shell, 2.0 ATA): ~$15,000–25,000 estimated

OxyRevo’s $2,500–5,500 price range for hard-shell 2.0 ATA access is structurally the most cost-effective entry to this pressure tier globally. The gap vs OxyHelp and Henshaw is $5,000–20,000 for nominally equivalent pressure specifications. The gap is explained by the China-direct sourcing, logistics cost differences, and the support-infrastructure gap that comes with US-domestic vs China-based after-sales.

Regulatory status & safety

Regulatory status: OxyRevo chambers are not FDA-cleared for the US market. The brand carries CE certification (EU MDR), Israeli Standard, ISO 9001, ISO 13485, and TUV certifications — meaningful for European, Middle Eastern, and international markets, but not equivalent to FDA 510(k) clearance for US regulatory purposes.

What CE certification means for US buyers: CE marking indicates conformity with European health, safety, and environmental protection standards. For medical devices, it requires compliance with EU MDR (Medical Device Regulation) — a meaningful regulatory standard. In the US market, CE certification is not recognized by the FDA as a substitute for 510(k) clearance. US buyers purchasing CE-certified, non-FDA-cleared chambers are operating outside the FDA device regulatory framework for their purchase.

Soft vs hard chamber distinction — mandatory: OxyRevo’s soft-shell chambers (~1.5 ATA) are in the “mild HBOT” category — above the 1.3 ATA of FDA-cleared consumer soft-shell options, but not within the 2.0–3.0 ATA range of clinical HBOT used for FDA-cleared medical indications. The hard-shell units at 2.0 ATA are structurally in the pressure range of clinical protocols, but without FDA clearance, clinical supervision, or the safety systems of hospital-grade multiplace installations. These are residential / wellness-use devices. FDA-cleared indications for HBOT (decompression sickness, CO poisoning, diabetic foot ulcers, radiation tissue damage, osteomyelitis, arterial insufficiency, and others) are clinical medical conditions requiring physician oversight — they do not apply to off-label residential wellness use.

Safety notice: Consult a physician before using HBOT in any form. Contraindications include untreated pneumothorax, Eustachian tube dysfunction, active upper respiratory infections, certain ear and sinus conditions, and concurrent use of specific medications. Hard-shell chambers at 2.0 ATA carry a higher risk profile for barotrauma than soft-shell 1.3 ATA chambers due to the greater pressure differential. Middle ear barotrauma is the most commonly reported adverse event in hyperbaric users. Oxygen toxicity is a known risk at higher pressures and extended exposures. Supervision protocols are advisable for first-time users of any hyperbaric chamber.

Import considerations for US buyers: Importing a non-FDA-cleared hyperbaric chamber for personal use falls in a regulatory gray zone. The FDA does not prohibit individuals from importing non-cleared devices for personal use in limited circumstances, but reselling non-cleared devices or using them in a commercial healthcare setting in the US creates additional regulatory complexity. US-based clinic operators should consult with a healthcare regulatory attorney before purchasing non-FDA-cleared hard-shell chambers for patient use.

Where it fits

Buy OxyRevo if:

• You are outside the US and CE certification is appropriate for your market — OxyRevo’s certification stack is robust for international deployment
• You want hard-shell 2.0 ATA access at the lowest global price point and are comfortable with China-direct sourcing and CE-only regulatory positioning
• You need a wheelchair-accessible hard-shell chamber — the Heal40 is the only option in this tier
• You want a recliner-format hard-shell (Space60) and cannot justify OxyHelp pricing (~2–3x higher for a similar format)
• You are a medspa or international clinical facility familiar with Chinese-direct equipment sourcing and have local technical support capability
• You are a biohacking practitioner or athlete in a non-US jurisdiction where FDA clearance is not the relevant regulatory framework

Look elsewhere if:

• You are a US buyer prioritizing FDA clearance — Newtowne (K051759) and Summit to Sea (K072757) are the FDA-cleared soft-shell options; no FDA-cleared residential hard-shell option exists at comparable pricing
• You want US-based warranty and technical support — OxyRevo’s support infrastructure is China-based; US warranty service logistics are a documented friction point
• You want soft-shell at 1.3 ATA with FDA clearance — Newtowne is $1,995 cheaper than OxyRevo’s soft-shell entry and carries FDA clearance
• You are a US clinical facility — deploying non-FDA-cleared devices in patient care settings requires careful regulatory analysis
• You have limited tolerance for customs / import logistics — China-direct shipping involves freight logistics, customs duties, and import documentation that European and US-domestic alternatives avoid

Verdict

OxyRevo earns a conditional verdict on the combination of its widest single-brand pressure range in the home/semi-clinical market (1.5 ATA soft-shell through 2.0 ATA stainless hard-shell), meaningful engineering credentials including heat-welded medical-grade TPU construction and 60+ design patents, the most comprehensive certification stack in the Chinese-direct hyperbaric tier (CE, ISO 9001, ISO 13485, TUV, Israeli Standard), unique product formats including the Space60 recliner and Heal40 wheelchair-accessible hard-shell, $2,500–5,500 pricing that is the most cost-effective entry to 2.0 ATA globally, and 3,000+ client deployments across 87 countries suggesting reliable production volume.

The “conditional” rating reflects two non-negotiable limitations: no FDA clearance for US buyers (the definitive US regulatory differentiator), and limited US support infrastructure for warranty and technical service. For a $2,500–5,500 purchase requiring long-term maintenance in a high-pressure mechanical device, support accessibility matters.

For international buyers, US buyers who have explicitly evaluated and accepted non-FDA-cleared positioning, or facilities in non-US jurisdictions where OxyRevo’s certification stack is appropriate, the brand offers genuinely competitive pressure-range, construction quality, and pricing. For US buyers who need FDA clearance, soft-shell alternatives (Newtowne, Summit to Sea) are the correct choice at 1.3 ATA — and no FDA-cleared residential hard-shell alternative currently exists at comparable pricing in the US market.

Changelog

• 2026-06-15: Review expanded with full body coverage: pressure-tier comparison table, soft-shell construction detail, hard-shell Space60 and Heal40 model analysis, patent and certification stack breakdown, cost-of-ownership comparison, regulatory status and safety section with FDA/CE distinction, import considerations for US buyers. Mandatory physician consultation and contraindications note added. Frontmatter lastUpdated corrected.
• 2026-05-07: Initial stub published based on OxyRevo published specifications, widest-pressure-range positioning, 60+ patents documentation, and aggregated user-report data.